According to Informa Connect’s recent meeting on specialty pharma, increased transparency is needed to avoid headaches stemming from federal surveillance and investigations. The meeting was held virtually and included insights from pharma experts.
“To prevent federal scrutiny, specialty pharmacies need to maintain their independent clinical judgment when entering into limited distribution network contracts with manufacturers. Clearly define which specialty pharmacy services are included in the contract and ensure that no incentives to purchase or prescribe specific therapies exist, because transparency is key to preventing legal challenges, according to legal experts at the 2021 Compliance Congress for Specialty Products.” Read more here.
(Source: Karen Blum, Specialty Pharmacy Continuum 6/24/21)